AstraZeneca has completed a $2 billion equity investment in Summit Therapeutics, locking in a deeper bet on one of oncology’s most closely watched experimental drug platforms and widening its U.S. research footprint.
AstraZeneca buys $2 billion stake in Summit Therapeutics
The cash infusion gives AstraZeneca more leverage over the development of ivonescimab, a first-in-class bispecific antibody aimed at PD-1 and VEGF, as the drug is tested across multiple tumor types, including in combination with antibody-drug conjugates. For investors, the deal matters because AstraZeneca is using capital, partnerships and trial access to build a broader cancer franchise at a time when large drugmakers are under pressure to replace aging revenue streams with late-stage assets.
Sentiment Indicators
AstraZeneca said it also signed a clinical collaboration with Summit to evaluate sonesitatug vedotin with ivonescimab and intends to pursue another agreement that would launch a global development program combining additional AstraZeneca cancer medicines. The company separately said its partnership with Daiichi Sankyo would test Datroway, or datopotamab deruxtecan, with ivonescimab in multiple tumor types, starting with a phase 3 trial in first-line triple-negative breast cancer.
The string of collaborations underscores AstraZeneca’s strategy of stitching together complementary oncology drugs rather than relying on one program alone. Ivonescimab sits at the center of that effort, and the broader combination approach could expand the addressable market if the trials show the therapies work better together than separately.
AstraZeneca shares rose 0.7% in London to 11,950 pence, though the stock is still down 6.1% over the past 12 months. On standard technical measures, the shares remain below the 200-day moving average, while the 50-day moving average sits above the current price, reflecting a still-cautious market backdrop despite the latest pipeline push.
The deal also fits a wider pattern of AstraZeneca stepping up U.S.-linked spending and development. The company has been expanding in Massachusetts and now has multiple clinical ties around Summit and Daiichi Sankyo, leaving oncology readouts and trial starts as the next key catalysts for the stock.
| Entity | Gains | Losses |
|---|---|---|
| AstraZeneca | ▲Broader cancer pipeline | ▼Near-term capital outlay |
| Summit Therapeutics | ▲$2 billion equity funding | ▼Greater dependence on partners |
| Daiichi Sankyo | ▲New combo-trial opportunity | ▼More clinical execution risk |
| Shareholders | ▲Pipeline optionality | ▼Dilution and trial uncertainty |
